Management of intermittent claudication: The importance of secondary prevention

European Journal of Vascular and Endovascular Surgery

Volumn 23, Issue 2, 2002, Pages 100-107

  Donnelly, R ^a,b   Yeung, J M C ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

ACE inhibitors; Atherosclerosis; Intermittent claudication; Secondary prevention

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PERINDOPRIL; PLACEBO; PRAVASTATIN; RAMIPRIL; SIMVASTATIN; WARFARIN; ANTICOAGULANT AGENT; ANTILIPEMIC AGENT;

ANKLE BRACHIAL INDEX; ARTERY DISEASE; ATHEROMA; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD GLUCOSE MONITORING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONSERVATIVE TREATMENT; DISEASE COURSE; DOSE RESPONSE; DRUG EFFECT; ENZYME INHIBITION; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HUMAN; INTERMITTENT CLAUDICATION; LIMB ISCHEMIA; LONG TERM CARE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SMOKING CESSATION; THROMBOSIS; BLOOD PRESSURE; CORONARY ARTERY DISEASE; FORECASTING; PERIPHERAL VASCULAR DISEASE; RISK FACTOR; SMOKING;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTICOAGULANTS; ANTILIPEMIC AGENTS; ASPIRIN; BLOOD PRESSURE; CORONARY DISEASE; FORECASTING; HUMANS; INTERMITTENT CLAUDICATION; PERIPHERAL VASCULAR DISEASES; RISK FACTORS; SMOKING; WARFARIN;

EID: 0036484636     PISSN: 10785884     EISSN: 15322165     Source Type: Journal    
DOI: 10.1053/ejvs.2001.1544     Document Type: Review

References (33)

1. MCKENNA M, WOLFSON S, KULLER L. The ratio of ankle and arm arterial pressure as an independent predictor of mortality. Atherosclerosis 1991; 87: 119-128.
2. VARNAUSKAS E, EUROPEAN CORONARY SURGERY STUDY GROUP. Twelve-year follow-up of survival in the randomised European Coronary Surgery Study. N Engl J Med 1988; 319: 332-337.
3. JONASON T, RINGQVIST I. Factors of prognostic importance for subsequent rest pain in patients with intermittent claudication. Acta Med Scand 1985; 218: 27-33.
4. HIRSCH AT, TREAT-JACOBSON D, LANDO HA, HATSUKAMI DK. The role of tobacco cessation, antiplatelet and lipid-lowering therapies in the treatment of peripheral arterial disease. Vasc Med 1997; 2: 243-251.
5. AMELI FM, STEIN M, PROVAN JL, PROSSER R. The effect of postoperative smoking on femoropopliteal bypass grafts. Ann Vasc Surg 1989; 3: 20-25.
6. ROSENBERG L, PALMER JR, SHAPIRO S. Decline in the risk of myocardial infarction among women who stop smoking. N Engl J Med 1990; 322: 214-217.
7. SILAGY C, MANT D, FOWLER G, LODGE M. Meta-analysis on efficacy of nicotine replacement therapies in smoking cessation. Lancet 1994; 343: 139-142.
8. HURT RD, SACHS DPL, GLOVER ED et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 1997; 337: 1195-1202.
9. GOLDHABER SZ, MANSON JE, STAMPFER MJ et al. Low-dose aspirin and subsequent peripheral arterial surgery in the Physician's Health Study. Lancet 1992; 340: 143-145.
10. HIRSH J, DALEN JE, FUSTER V, HARKER LB, SALZMAN EW. Aspirin and other anti-platelet drugs: the relationship between dose, effectiveness, and side effects. Chest 1992; 102: 327S-336S.
11. CLAGGETT GP, GRAOR RA, SALZMAN EW. Antithrombotic therapy in peripheral arterial disease. Chest 1992; 102: 516S-528S.
12. THE DUTCH TIA TRIAL STUDY GROUP. A comparison of two doses of aspirin (30 mg vs 283 mg a day) in patients after a transient ischaemic attack or minor ischaemic stroke. N Engl J Med 1991; 325: 1261-1266.
13. CAPRIE STEERING COMMITTEE. A randomised, blinded trial of clopidogrel vs aspirin in patients at risk of ischaemic events. (CAPRIE). Lancet 1996; 348: 1329-1339.
14. CLOPIDOGREL IN UNSTABLE ANGINA TO PREVENT RECURRENT EVENTS (CURE) TRIAL INVESTIGATORS. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.
15. STROKE PREVENTION IN ATRIAL FIBRILLATION INVESTIGATORS. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke prevention in Atrial Fibrillation II study. Lancet 1994; 343: 687-691.
16. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival (4S) study. Lancet 1994; 344: 1383-1389.
17. SACKS FM, PFEFFER MA, MOYE LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-1009.
18. LENG GC, PRICE JF, JEPSON RG. Cochrane review: lipid-lowering therapy in the treatment of lower limb atherosclerosis. Eur J Vasc Endovasc Surg 1998; 16: 5-6.
19. PEDERSON TR, KJEKSHUS J, PYORALA K et al. Effect of simvastatin on ischaemic signs and symptoms in the Scandinavian Simvastatin Survival (4S) study. Am J Cardiol 1998; 81: 333-335.
20. MURABITO JM, D'AGOSTINO RB, SILBERSHATZ H, WILSON PWF. Intermittent claudication: A risk profile from The Framingham Heart Study. Circulation 1997; 96: 44-49.
21. BLOOD PRESSURE LOWERING TREATMENT TRIALISTS COLLABORATION. Effects of ACE inhibitors, calcium antagonists, and other blood pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 2000; 355: 1955-1964.
22. HANSSON L, ZANCHETTI A, CARRUTHERS SG et al. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-1762.
23. PROGRESS COLLABORATIVE GROUP. Randomised trial of a perindopril-based blood pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033-1041.
24. THE HEART OUTCOMES PREVENTION EVALUATION (HOPE) STUDY INVESTIGATORS. Effects of an angiotensin converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-153.
25. THE BYPASS ANGIOPLASTY REVASCULARIZATION INVESTIGATION (BARI) INVESTIGATORS. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. N Engl J Med 1996; 335: 217-225.
26. DONNELLY R, EMSLIE-SMITH A, GARDINER I, MORRIS A. Vascular complications of diabetes. Br Med J 2000; 320: 1062-1066.
27. ADLER AI, STRATTON IM, ANDREW H et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. Br Med J 2000; 321: 412-419.
28. KHAW K-T, WAREHAM N, LUBEN R et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk). Br Med J 2001; 322: 15-22.
29. LONN EM, YUSUF S, DZAVIK V et al. Effects of ramipril and vitamin E on atherosclerosis: The study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation 2001; 103: 919-925.
30. MEHTA SR, YUSUF S, PETERS RJG et al. Effects of pre-treatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358: 527-533.
31. DUPUIS J, TARDIF J-C, CERACEK P, THEROUX P. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. Circulation 1999; 99: 3227-3233.
32. AOKI M, MORISHITA R, HAYASHI S et al. Inhibition of neointimal formation after balloon injury by cilostazol, accompanied by improvement of endothelial dysfunction and induction of hepatocyte growth factor in rat diabetes model. Diabetologia 2001; 44: 1034-1042.
33. LEE T-M, SU S-F, TSAI C-H, LEE Y-T, WANG S-S. Differential effects of cilostazol and pentoxifylline on vascular endothelial growth factor in patients with intermittent claudication. Clin Science 2001; 101: 305-311.